Although other countries have posted less spending on biologics Humira, Enbrel and Remicade, the U.S. continues to buy the drugs despite their growing prices.
Madison.Com reports U.S. spending on the three drugs has so far reached a combined $21 billion this year.
However, biosimilars have given the three blockbuster drugs a run for their money in other countries.
Johnson and Johnson’s Remicade through the European Union, Russia and Turkey has plunged from $2.37 billion in sales in 2014 to only $874 million so far this year, with Pfizer’s biosimilar, Inflectra, being the main competitor. Inversely, the same J&J drug printed an 8-percent sales increase in the U.S. over the same period to reach a $4.4 billion run rate.
But biosimilars appear to be having more difficulty in the U.S., evidenced by Pfizer’s struggling Inflectra numbers, only printing $40 million in sales through the first half of 2017.